Clinical trial
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
NCT00005005 · Dennis Black, Other · Completed
Key facts
| NCT number | NCT00005005 |
|---|---|
| Title | PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis |
| Official title | Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis |
| Lead sponsor | Dennis Black, Other |
| Collaborators | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | PTH, Alendronate |
| Enrollment | 238 |
| Start date | Oct 1, 1999 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Mar 27, 2000 |
| Last update posted | Feb 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: